Recently, a large clinical study with 891 participants for evaluating Berberine's efficacy in the prevention of recurrence of colorectal adenoma (CRA) was carried out.[12] Berberine treatment effectively reduced CRA recurrence rate by ≈11% (recurrence rate is 47% in placebo‐treated group while 36% in Berberine treated group) implying a heterogenous response of CRAs to Berberine treatment.[12] In order to assess the possible correlation between Berberine responders and the status of NNMT/DNMT1, we did a retrospective study with the CRA samples collected in this clinical trial. This evidence concerns the gene DNMT1 and colorectal adenoma.